Checkpoint Therapeutics reports Q1 results; cosibelimab BLA resubmission targeted for mid-2024

Checkpoint Therapeutics, Inc.

2024-Q1 EPS reported -$0.33

Cash and equivalents $11.2M at March 31, 2024, up from $4.9M at Dec 31, 2023 after $14.0M offering.
Net loss $10.9M ($0.33/sh) vs $10.5M ($0.89/sh) in Q1 2023; R&D expenses fell to $8.5M from $15.8M.
Third-party CMO submitted response to FDA inspection deficiencies from Dec 2023 CRL; company plans FDA meeting for mid-year BLA resubmission.
Board appointed Dr. Amit Sharma, VP at Alexion/AstraZeneca, as non-executive director in March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Checkpoint Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $10.9 million, EPS $0.33 per share.

Period: first quarter ended March 31, 2024
Net income: $10.9 million
EPS: $0.33 per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the first quarter of 2024 was $10.9 million, or $0.33 per share

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-059667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.